prematurity. Disorders related to short gestation and low birth weight, not elsewhere classified
Conditions
Interventions
Intervention 1: In this group , Aminophylline will be administered from the first day of birth and will be continued at least for 5 days , if there is any need , the drug will be continue af
Treatment - Drugs
In this group , Aminophylline will be administered from the first day of birth and will be continued at least for 5 days , if there is any need , the drug will be continue after this period
In this group no methylxanthine therapy will be administered as a prophylaxis during the first 48 hr of life . But after this period the drug can be started according to clinical necessities
Sponsors
Shiraz University of Medical Science
Eligibility
Sex/Gender
All
Age
No minimum to 1 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria : neonates with the gestational age of 36 weeks or lower; birth weight of equal or lower than 2000 gr exclusion criteria: major congenital anomaly; severe congenital heart disease; discontinuation of drug before 5 days; a clinical necessary for starting a methylxanthine drug during the first 48 hours of life in control group
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mechanical ventilation. Timepoint: along the study. Method of measurement: the days of ventilator dependency recorded on baby sheet.;Chronic lung disease. Timepoint: along the study. Method of measurement: oxygen dependency after 14 days of life. | — |
Secondary
| Measure | Time frame |
|---|---|
| Intracranial hemorrhage. Timepoint: a long the addmission. Method of measurement: sonography.;Necrotizing enterocolitis. Timepoint: a long the addmission. Method of measurement: clinical and radiological.;Retinopathy of prematurity. Timepoint: a long the addmission and after discharge. Method of measurement: ophtalmologic examination.;Neonatal mortality. Timepoint: a long the addmission. Method of measurement: clinical.;Tachycardi. Timepoint: along the drug administration. Method of measurement: heart monitoring.;Other drug side effects. Timepoint: along the drug administration. Method of measurement: clinical. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr.Hamid Mousavi
Shiraz University Of Medical Science
Outcome results
None listed